Vor Biopharma/$VOR
1D1W1MYTD1Y5YMAX
Capital at risk
About Vor Biopharma
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
- Ticker
- $VOR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Boston, United States
- Website
- www.vorbio.com
Vor Biopharma Metrics
BasicAdvanced
$1.5B
1.24
$20.19
1.72
-
Price and volume
Market cap
$1.5B
Beta
1.72
52-week high
$49.95
52-week low
$6.50
Average daily volume
752K
Financial strength
Current ratio
19.147
Quick ratio
18.785
Long term debt to equity
-1.27
Total debt to equity
-1.437
Profitability
EBITDA (TTM)
-117.285
Management effectiveness
Return on assets (TTM)
-21.37%
Return on equity (TTM)
-73.60%
Valuation
Price to earnings (TTM)
1.243
Price to book
-6.83
Price to tangible book (TTM)
-6.83
Price to free cash flow (TTM)
-5.542
Free cash flow yield (TTM)
-18.04%
Free cash flow per share (TTM)
-4.529
Growth
Earnings per share change (TTM)
-105.89%
3-year earnings per share growth (CAGR)
-19.81%
Bulls say / Bears say
China’s NMPA granted conditional approval for telitacicept to treat adult IgA nephropathy and full approval for Sjögren’s disease via collaborator RemeGen, marking the first BAFF/APRIL inhibitor cleared in these indications (SEC EDGAR)
Results from the Phase 3 TELIGAN trial were published in The New England Journal of Medicine, showing a 58.9% reduction in 24-hour urinary protein-to-creatinine ratio at week 39 versus 8.8% for placebo, underscoring strong efficacy (Investing.com)
As of December 31, 2025, Vor held approximately $450 million in cash, cash equivalents, and short-term investments, providing runway into mid-2028 to fund key clinical and regulatory milestones (Vor 8-K)
Vor Biopharma’s Q2 2026 EPS of –$0.80 missed consensus estimates of –$0.69, reflecting wider losses than expected and dampening near-term sentiment (MarketBeat)
Vor registered an S-3 filing in February 2026 to allow resale of up to 13.8 million shares from a December private placement, posing significant dilution risk to existing shareholders (Vor 424B3)
Vor Biopharma posted a wider-than-expected Q2 loss driven by increased G&A costs as it scales global development of telitacicept, highlighting heavy overhead burden (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 23 Aug 2026.
Upcoming events
No upcoming events
Funds containing Vor Biopharma
AllUSDGBPEUR
Fund name | Fund size | $VOR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.